A Phase III clinical trial found that nicotinamide riboside, an NAD-boosting supplement, did not slow Parkinson’s disease.

For Premal Shah, PhD, CEO of clinical whole-genome analysis company MyOme, the idea that he might be at high risk for a heart attack is not abstract—it is personal history. “My dad had a heart attack ...

A single tRNA can influence whether prostate cancer cells mutate and become difficult to treat with standard therapies.

An analysis of multiple cancer types has revealed mitochondrial DNA copy number as a key determinant of mutational load and ...

Statin use was associated with a lower risk of open-angle glaucoma and less need for surgery, laser treatment, and ...

Simultaneously reprogramming immune cells and strengthening T cells can make glioblastoma tumors shrink and prevent ...

A short peptide reduced chronic pain-like behaviors in mice without disrupting the acute pain signals that help protect ...

Researchers have identified a previously unrecognized protective role for the brain’s immune cells in people with Parkinson’s disease.

Nuclear localization of fumarylacetoacetate hydrolase is associated with CDK4/6 inhibitor resistance in hormone receptor ...

Chemotherapy could make cancer vaccines more effective, and adding PD-1 blockade to the mix could be even better, according to new research from the Oxford Branch of the Ludwig Institute for Cancer ...

HPV vaccination before pregnancy lowers the risk of major birth complications, offering benefits beyond reducing the risk of ...

The way people speak may reveal important clues about their brain health and point to early signs of cognitive decline.